Testing effectiveness (Phase 2)Ended earlyNCT01033019
What this trial is testing
To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)
Who this might be right for
Sporadic Superficial and Nodular Skin Basal Cell Carcinomas
Novartis Pharmaceuticals 25